Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Cash from Operations (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Cash from Operations data on record, last reported at 32863000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations rose 13.23% year-over-year to 32863000.0; the TTM value through Dec 2025 reached 156115000.0, down 26.84%, while the annual FY2025 figure was 156115000.0, 26.84% down from the prior year.
  • Cash from Operations reached 32863000.0 in Q4 2025 per AMPH's latest filing, down from 52583000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 69109000.0 in Q2 2024 and bottomed at 2569000.0 in Q3 2021.
  • Average Cash from Operations over 5 years is 37008950.0, with a median of 35334500.0 recorded in 2025.
  • Peak YoY movement for Cash from Operations: tumbled 91.25% in 2022, then soared 1851.08% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 40441000.0 in 2021, then crashed by 62.35% to 15226000.0 in 2022, then skyrocketed by 56.73% to 23864000.0 in 2023, then grew by 21.62% to 29024000.0 in 2024, then increased by 13.23% to 32863000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 32863000.0 in Q4 2025, 52583000.0 in Q3 2025, and 35592000.0 in Q2 2025.